Peripheral Vascular Articles & Analysis
44 news found
Embrace HES is the first liquid embolic hydrogel for peripheral arterial embolization of hypervascular tumors, which often occur in the liver, kidney, and bone. ...
A cardiac puzzle This procedure, like the one before it, was conducted with the assistance of Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, and EchoPixel’s chief medical officer. The patient had come to the facility with shortness of breath and fatigue, which continued even after ...
Whealon served as Vice President of Research and Development for the Peripheral Vascular business at Medtronic where he was responsible for product development across three worldwide sites. ...
” Confluent supports some of the fastest growing medical device markets such as Interventional Neurovascular, Electrophysiology, Structural Heart, and Peripheral Vascular. As a result of the double-digit growth of these currently served markets, a substantial number of new products are coming into production and will utilize this new facility space ...
“The funding we have secured will allow REVA to move forward with our pivotal clinical trial to support FDA approval of our MOTIV peripheral vascular scaffold as well as to obtain FDA clearance of our TyroSphere bioresorbable embolic bead technology.” REVA’s MOTIV device represents a unique breakthrough technology for the treatment of patients ...
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. ...
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023 Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular ...
ByRobocath
The randomized, placebo-controlled, double-blind Phase II study investigates the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral vascular blood flow in patients with systemic sclerosis. In total, 69 patients have been recruited to the study. ...
The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of bioresorbable stent that prevents the complications associated with metal stents. Severe peripheral vascular disease (PVD) is caused by the formation of blockages ...
Aliso Viejo, CA – June 7, 2022 – Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to ...
Among the most innovative MedTech emerging companies, KLISBio is keen to deal-make and establish strong relations with active investors and paramount players in the life science and regenerative medicine space, aiming to contribute to the advancement of the whole industry with SILKBridge®, KLISBio’s first product in pipeline for peripheral nerve repair. ...
ByKLISBio
Significant challenges in treating peripheral nerve injuries persist within the domain of surgery and regenerative medicine, having a profound impact on patients’ quality of life. ...
ByKLISBio
Among the best innovators in orthopedics, biologics and regenerative medicine participating in CG Musculoskeletal Conference, KLISBio is open to expand its network and build strong relations with investors and industry leaders, in the attempt to move forward the current standard of care in peripheral nerve repair with SILKBridge®, KLISBio’s first product in pipeline for ...
ByKLISBio
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional ...
Among the most innovative MedTech emerging companies, KLISBio is keen to deal-make and establish strong relations with active investors and paramount players in the life science and regenerative medicine space, aiming to contribute to the advancement of the whole industry with SILKBridge®, KLISBio’s first product in pipeline for peripheral nerve repair. ...
ByKLISBio
During diabetic foot ulcer episodes-of-care, individuals are 30 times more likely to have a lower limb amputation, eight times more likely to be hospitalized for peripheral vascular disorders, and about two times more likely to be hospitalized for renal failure, congestive heart failure (CHF), pulmonary edema, chronic obstructive pulmonary disease (COPD), or a ...
Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. ...
ByKLISBio
Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated to be available for clinical use in 2023. ...
ByKLISBio
Confluent provides a broad range of capabilities including developing and manufacturing components, delivery systems and finished devices for medical device OEMs in many of the fastest growing healthcare subsectors, including neurovascular, structural heart, electrophysiology, aortic intervention, peripheral vascular and ENT. Confluent is a strategic partner to a ...